- Home
- CMMB vs GENK Comparison
CMMB vs GENK Comparison
Compare CMMB & GENK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- GENK
- Stock Information
- Founded
- CMMB 2004
- GENK 2011
- Country
- CMMB Israel
- GENK United States
- Employees
- CMMB N/A
- GENK N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- GENK Restaurants
- Sector
- CMMB Health Care
- GENK Consumer Discretionary
- Exchange
- CMMB Nasdaq
- GENK Nasdaq
- Market Cap
- CMMB 13.7M
- GENK 16.3M
- IPO Year
- CMMB N/A
- GENK 2023
- Fundamental
- Price
- CMMB $2.58
- GENK $2.78
- Analyst Decision
- CMMB Strong Buy
- GENK Strong Buy
- Analyst Count
- CMMB 2
- GENK 2
- Target Price
- CMMB $26.50
- GENK $7.00
- AVG Volume (30 Days)
- CMMB 151.5K
- GENK 61.1K
- Earning Date
- CMMB 11-12-2025
- GENK 11-07-2025
- Dividend Yield
- CMMB N/A
- GENK 4.36%
- EPS Growth
- CMMB N/A
- GENK N/A
- EPS
- CMMB N/A
- GENK N/A
- Revenue
- CMMB N/A
- GENK $216,137,000.00
- Revenue This Year
- CMMB N/A
- GENK $12.35
- Revenue Next Year
- CMMB N/A
- GENK $14.62
- P/E Ratio
- CMMB N/A
- GENK N/A
- Revenue Growth
- CMMB N/A
- GENK 10.67
- 52 Week Low
- CMMB $2.39
- GENK $2.65
- 52 Week High
- CMMB $9.84
- GENK $10.33
- Technical
- Relative Strength Index (RSI)
- CMMB 38.12
- GENK 40.95
- Support Level
- CMMB $2.95
- GENK $2.75
- Resistance Level
- CMMB $2.80
- GENK $3.02
- Average True Range (ATR)
- CMMB 0.26
- GENK 0.16
- MACD
- CMMB -0.09
- GENK -0.01
- Stochastic Oscillator
- CMMB 2.30
- GENK 17.74
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.